Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of VELCADE (Bortezomib), Nipent (Pentostatin), and Rituxan (Rituximab) (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma

NCT01460602 is registered in ClinicalTrials.gov with Louisiana State University Health Sciences Center Shreveport as lead sponsor.

NCT NCT01460602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01460602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of VELCADE (Bortezomib), Nipent (Pentostatin), and Rituxan (Rituximab) (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Phase
Phase 1/2
Overall status
Withdrawn
Start date
May 31, 2010
Completion date
October 31, 2014
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma